On 16 December 2010 the ACCC accepted an undertaking (the Undertaking) from Aspen Pharmacare Holdings Limited and Aspen Asia Pacific Pty Ltd (together, Aspen) in relation to Aspen's proposed acquisition of Sigma Pharmaceuticals Limited's Pharmaceutical Division.
The Undertaking provides for Aspen to divest all products containing prednisone and prednisolone which are currently marketed and supplied by Sigma under the Sone and Solone brand names respectively and all products containing penicillin V which are currently marketed and supplied by Aspen under the LPV brand name.
The Undertaking aims to maintain competition through the creation of a viable, effective, stand-alone, independent and long term competitor for the supply of each of the divested products.
